ChinaBio Today -- Sinocom Pharmaceutical, Inc., a Nevada corporation with operations in China, raised $15 million by placing shares of its Series A Preferred Stock with qualified investors. Seavi Advent Private Equity, the South East Asia branch of Boston-based Advent International, contributed $7 million of the funding. The Series A investors will collectively own 18% of the company if they convert all of their Preferred Stock into common shares
